[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skeletal-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skeletal-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100578283","observational-prospective-pmcf-study-to-confirm-performance-and-safety-of-intelect-devices-in-real-world-100578283",false,"NCT06809283","Observational Prospective PMCF Study to Confirm Performance and Safety of Intelect® Devices in Real World","Observational Prospective Post Market Clinical Follow-up (PMCF) Study to Confirm the Performance and Safety of the Chattanooga Intelect® Devices in Real World Use","INTELECT","Inclusion Criteria:\n\n1. Patients with musculoskeletal and skeletal muscle deficit disorders assigned to be treated with any of the Intelect® devices according to the current clinical practice at the selected sites and based on the opinion of the Investigator.\n2. Patient male or female with age ≥18 years old.\n3. Patient able to provide written informed consent. For France only: To be affiliated to the social security system or to be beneficiary of such system\n\nExclusion Criteria:\n\n1. Patients participating in another clinical study or who have completed a clinical study less than 30 days prior to enrollment.\n2. Patients who for any reason e.g. significant co-morbidities or other reasons, are considered by the Investigator unsuitable for study participation.","ALL","18 Years",{"count":20,"type":21},144,"ESTIMATED","OBSERVATIONAL","DJO UK Ltd (ENOVIS) is conducting this study to confirm the performance and safety of the Chattanooga Intelect® devices in real world use. This study will record post market clinical data on the use of a number of MDR-CE marked devices that are part of the Chattanooga Intelect® device family to ensure the continued acceptability of the benefit-risk ratio, and to identify possible systematic misuse or off-label use of the devices (Intelect® Mobile 2 Combo, Intelect® Mobile 2 Ultrasound, Intelect® Mobile 2 Electrotherapy (Stim), Intelect® Transport 2 Combo and Intelect® Transport 2 Ultrasound).",[25,26,27],"Musculoskeletal Disorders","Skeletal Disorder","Muscle Disorder",[29,30,31,32,33],"TENS","NMES","Ultrasound","Pain","ROM","RECRUITING","2025-11-14",{"date":37,"type":38},"2025-11-17","ACTUAL",{"date":40,"type":38},"2025-03-10",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"DJO UK Ltd","INDUSTRY",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100506594","decoding-the-genetic-landscape-of-skeletal-diseases-100506594","NCT05876416","Decoding the Genetic Landscape of Skeletal Diseases","SKDLAND","Inclusion Criteria:\n\nClinically suspected skeletal dysplasia based on previous investigations\n\nAbnormal height\n\nRadiographic abnormalities of the skeleton in addition to other syndromic features\n\nHealthy relatives of the affected study participants\n\nExclusion Criteria:\n\nNo radiographic data available from clinical investigations\n\nSuspected environmental or multifactorial causes",true,{"count":56,"type":21},450,"This 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders (GSDs); (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different GSD groups. For patients with unsolved GSD, the investigators search for molecular causes of GSDs using whole genome sequencing (WGS) and total ribonucleic acid (RNA) sequencing. Candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. Causality of the new variants is studied in cells and in transgenic mice models. Molecular and clinical findings are summarized for different GSD groups.",[59,60,61,26],"Genetic Skeletal Diseases","Skeletal Dysplasia","Molecular Causes","2023-05-16",{"date":64,"type":38},"2023-05-25",{"date":66,"type":38},"2015-01-01",{"date":68,"type":21},"2026-12-31",{"name":70,"class":71},"Karolinska Institutet","OTHER",1]